Dr Karl Peggs

Dr Karl PeggsTel: 020 3447 9712
Fax: 020 3447 9571
Email: k.peggs@ucl.ac.uk

University College Hospital

Blood Diseases (clinical haematology)

Professional background

Karl Peggs is a Senior Lecturer in Stem Cell Transplantation and Immunotherapy at UCL and Honorary Consultant in Haematology/Transplantation at UCL Hospitals. He received his preclinical training and MA at Cambridge University, completing his clinical training at Oxford University Medical School. Following qualification he completed general medical training at Addenbrookes Hospital Cambridge, and specialist haematology training at the John Radcliffe Hospital, Oxford and subsequently UCLH, London. During this time he spent three years in the research group of Professor Stephen Mackinnon, establishing adoptive cellular therapies for cytomegalovirus. After taking the position of Senior Lecturer at UCL in 2003, he spent 2 years at Memorial Sloan Kettering Cancer Institute, New York, in the laboratory of Professor James Allison, studying murine models of regulatory checkpoint blockade.
His research interests include immune reconstitution, pathogen-specific adoptive cellular therapies, and regulatory checkpoint-directed immunotherapeutics. He is member of the Leukaemia and Lymphoma Research Clinical Trials Committee, a Trustee of the Teens Unite charity, and has contributed to several international working parties on infectious complications and relapse following stem cell transplantation. He is Chief Investigator for 4 UKCRN national studies investigating transplantation in Hodgkin Lymphoma and cellular therapies for cytomegalovirus.

Research interests

  • Stem cell transplantation 
  • Immune reconstitution 
  • Viral infections 
  • Adoptive cellular therapy 
  • Hodgkin's and non-Hodgkin's lymphomas


Peggs KS, Quezada SA, Sharma P, Allison JP. Chapter 13: Cancer immunotherapy. Cancer Medicine 8. 2009. Ed. Hong WK. Elsevier. ISBN 978-1-607-950-141.   
Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007 Sep;12(3):192-9.   
Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010 Mar; 207(3):637-50.   
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the anti-tumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug; 206(8):1717-25.   
Peggs KS, Quezada SA, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008 Sep; 205(9):2125-38.   
Peggs KS, Quezada S, Curran M, Allison JP. CTLA-4 blockade and GMCSF combination immunotherapy increases effector frequencies altering the intra-tumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul; 116(7):1935-45.   
Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Background to HCT, including posttransplant immune recovery. Biol Blood Marrow Transplant. 2009 Oct;15:1147-53.   
Peggs KS, Krauss A, Mackall C. Clinical implications of immune reconstitution following autologous and allogeneic transplantation. Cancer Treatment and Research: Hematopoietic Stem Cell Transplantation. 2008. 144. Ed. Bishop MR and Rosen ST. Springer. ISBN 978-0-387-78579-0: 131-54.   
Peggs KS, Verfuerth S, Pizzey A, et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional anti-viral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009 Dec; 49(12):1851-60.   
Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther. 2009 Jun; 9(6): 725-36.    
Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T-cell lines. Lancet. 2003 Oct; 362:1375-1377.   
Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin Lymphoma. Br J Haematol. 2008 Nov; 143(4): 468-80.   
Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007 Oct; 139(1):70-80.   
Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s Lymphoma effect following reduced intensity allogeneic transplantation. Lancet. 2005 Jun 4;365:1934-1941.   
Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation for non-Hodgkin’s lymphoma. Br J Haematol. 2005 Jan;128(2): 153-168.   
Thomson K, Morris E, Milligan D, Parker A, Hunter A, Cook G, Bloor A, Clark F, Kazmi M, Linch D, Chakraverty R, Peggs K, Mackinnon S. T cell depleted reduced intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010.   
Thomson KJ, Morris EC, Bloor A, Cook G, Miligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. Favorable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkin’s Lymphoma. J Clin Oncol. 2009 Jan; 27(3):426-32.   
Peggs KS. The role of alemtuzumab in allogeneic stem cell transplantation. Immunotherapy of Lymphoid Malignancies.  2005. Ed. Hillmen P and Witzig TE. Atlas Medical Publishing Ltd. ISBN 1-904392-52-0.   
Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning. Blood. 2010.

GMC/GDC number: 3558393